GenMark Posts 162 Percent Revenue Growth; Seeks New CEO

The firm said that it saw particularly strong growth for its reagent test revenues as it reported its first quarterly results as a publicly traded company in the US.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories